OverviewSuggest Edit

Exagen is a biotechnology company engaged in transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. The company is the provider of AVISE testing, offering physicians diagnostic, prognostic and monitoring tools in the area of rheumatology and autoimmune diseases.
TypePublic
Founded2002
HQVista, US
Websiteexagen.com
Employee Ratings3.1

Latest Updates

Employees (est.) (Jun 2019)144
Job Openings4
Revenue (FY, 2018)$32.4 M(+22%)
Share Price (Feb 2020)$18.1

Key People/Management at Exagen

Ron Rocca

Ron Rocca

President & CEO
Thierry Dervieux

Thierry Dervieux

Chief Scientific Officer, Medical Director, New York
Kamal Adawi

Kamal Adawi

Chief Financial Officer
Arthur Weinstein

Arthur Weinstein

Chief Medical Officer
Claudia Ibarra

Claudia Ibarra

Senior Vice President Laboratory Operations
Mark Hazeltine

Mark Hazeltine

Vice President of Finance & Corporate Development
Show more

Exagen Office Locations

Exagen has an office in Vista
Vista, US (HQ)
1261 Liberty Way
Show all (1)

Exagen Financials and Metrics

Exagen Revenue

Embed Graph
View revenue for all periods
Exagen's revenue was reported to be $32.44 m in FY, 2018 which is a 21% increase from the previous period.
USD

Revenue (Q3, 2019)

10.4m

Gross profit (Q3, 2019)

5.7m

Gross profit margin (Q3, 2019), %

54.2%

Net income (Q3, 2019)

(3.1m)

EBIT (Q3, 2019)

(2.2m)

Market capitalization (11-Feb-2020)

227.7m

Closing stock price (11-Feb-2020)

18.1

Cash (30-Sept-2019)

77.8m

EV

181.7m
Exagen's current market capitalization is $227.7 m.
Annual
USDFY, 2017FY, 2018

Revenue

26.8m32.4m

Revenue growth, %

21%

Cost of goods sold

14.1m15.4m

Gross profit

12.7m17.1m
Quarterly
USDQ3, 2019

Revenue

10.4m

Cost of goods sold

4.8m

Gross profit

5.7m

Gross profit Margin, %

54%
Annual
USDFY, 2017FY, 2018

Cash

11.2m13.2m

Accounts Receivable

604.0k6.0m

Prepaid Expenses

1.4m2.2m

Current Assets

20.4m28.9m
Quarterly
USDQ2, 2019Q3, 2019

Cash

16.2m77.8m

Accounts Receivable

6.7m6.2m

Prepaid Expenses

2.0m1.7m

Current Assets

33.1m85.8m
Annual
USDFY, 2017FY, 2018

Net Income

(25.6m)(8.0m)

Depreciation and Amortization

670.0k731.0k

Accounts Payable

44.0k(824.0k)

Cash From Operating Activities

(11.0m)(9.3m)
Quarterly
USDQ2, 2018Q2, 2019Q3, 2019

Net Income

(4.9m)(5.5m)(8.6m)

Depreciation and Amortization

378.0k363.0k

Accounts Payable

(449.0k)(173.0k)174.0k

Cash From Operating Activities

(5.4m)(4.1m)(5.8m)
USDY, 2019

EV/EBIT

-84.2 x

EV/CFO

-31.4 x

Financial Leverage

1.6 x
Show all financial metrics

Exagen Operating Metrics

FY, 2018Q2, 2019

Medical Tests Delivered (AVISE)

83 k50.79 k

Medical Tests Delivered Since Inception (AVISE)

326 k

Physicians Reached

1.30 k1.71 k

Product Lines

7
Show all operating metrics

Exagen Revenue Breakdown

Embed Graph

Exagen revenue breakdown by business segment: 65.0% from Healthcare insurers, 30.9% from Government and 4.1% from Other

Exagen Online and Social Media Presence

Embed Graph

Exagen News and Updates

Exagen extends agreement with GSK for a third year to drive greater awareness about challenges facing lupus diagnosis and management

SAN DIEGO, Nov. 22, 2019 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention, today ann…

Exagen Inc. to Participate in the 31st Annual Piper Jaffray Healthcare Conference on December 5, 2019

SAN DIEGO, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention, today ann…

Exagen Blogs

Exagen and the University of Washington Collaborate on Lupus and Rheumatoid Arthritis Research

The post Exagen and the University of Washington Collaborate on Lupus and Rheumatoid Arthritis Research appeared first on Exagen Inc..

Exagen Inc. Expands Board of Directors with its Appointment of Chet Burrell, Tina Nova and Bruce Robertson

The post Exagen Inc. Expands Board of Directors with its Appointment of Chet Burrell, Tina Nova and Bruce Robertson appeared first on Exagen Inc..

Exagen Inc. Completes $22.6 Million Financing

The post Exagen Inc. Completes $22.6 Million Financing appeared first on Exagen Inc..

Exagen Frequently Asked Questions

  • When was Exagen founded?

    Exagen was founded in 2002.

  • Who are Exagen key executives?

    Exagen's key executives are Ron Rocca, Thierry Dervieux and Kamal Adawi.

  • How many employees does Exagen have?

    Exagen has 144 employees.

  • What is Exagen revenue?

    Latest Exagen annual revenue is $32.4 m.

  • What is Exagen revenue per employee?

    Latest Exagen revenue per employee is $225.3 k.

  • Who are Exagen competitors?

    Competitors of Exagen include Affinivax, OxThera and Universal Biosensors.

  • Where is Exagen headquarters?

    Exagen headquarters is located at 1261 Liberty Way, Vista.

  • Where are Exagen offices?

    Exagen has an office in Vista.

  • How many offices does Exagen have?

    Exagen has 1 office.